Literature DB >> 34483762

Tardive Dyskinesia: Spotlight on Current Approaches to Treatment.

Sarah M Debrey1, David R Goldsmith1.   

Abstract

Tardive dyskinesia (TD) is a debilitating, iatrogenic, and potentially severe movement disorder characterized by involuntary, repetitive, purposeless movements that are present throughout the body. The authors present a review of studies of past, current, and possible future treatment approaches to the management of TD; consider the phenomenology, assessment, and putative pathophysiological mechanisms of TD, early pharmacological trials, a focus on the newer vesicular monoamine transporter 2 inhibitors, and other evidence-based approaches, such as clozapine; and present preliminary evidence for newer approaches, such as deep brain stimulation and repetitive transcranial magnetic stimulation. On the basis of the evidence presented here, the authors highlight the importance of early recognition and assessment of TD, as well as how to best approach management of these often incapacitating symptoms.
Copyright © 2021 by the American Psychiatric Association.

Entities:  

Keywords:  Clozapine; Schizophrenia; Tardive Dyskinesia; VMAT-2 Inhibitor

Year:  2021        PMID: 34483762      PMCID: PMC8412148          DOI: 10.1176/appi.focus.20200038

Source DB:  PubMed          Journal:  Focus (Am Psychiatr Publ)        ISSN: 1541-4094


  72 in total

1.  Effect of donepezil on tardive dyskinesia.

Authors:  Adeleke Ogunmefun; Mehrul Hasnain; Akhtar Alam; Theodore Osuala; William T Regenold
Journal:  J Clin Psychopharmacol       Date:  2009-02       Impact factor: 3.153

2.  Low-dose propranolol in tardive dyskinesia.

Authors:  N M Bacher; H A Lewis
Journal:  Am J Psychiatry       Date:  1980-04       Impact factor: 18.112

3.  Deep brain stimulation for tardive syndromes: Systematic review and meta-analysis.

Authors:  Antonella Macerollo; Günther Deuschl
Journal:  J Neurol Sci       Date:  2018-02-05       Impact factor: 3.181

Review 4.  VMAT2 inhibitors for the treatment of tardive dyskinesia.

Authors:  Laura M Scorr; Stewart A Factor
Journal:  J Neurol Sci       Date:  2018-02-05       Impact factor: 3.181

5.  Pallidal and thalamic neurostimulation in severe tardive dystonia.

Authors:  T Trottenberg; G Paul; W Meissner; K Maier-Hauff; C Taschner; A Kupsch
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-04       Impact factor: 10.154

6.  Pharmacologic Treatment of Tardive Dyskinesia: A Meta-Analysis and Systematic Review.

Authors:  Bekir B Artukoglu; Fenghua Li; Natalia Szejko; Michael H Bloch
Journal:  J Clin Psychiatry       Date:  2020-05-26       Impact factor: 4.384

7.  Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial.

Authors:  Stanley N Caroff; Patricia Walker; Cabrina Campbell; Alan Lorry; Christopher Petro; Kevin Lynch; Robert Gallop
Journal:  J Clin Psychiatry       Date:  2007-03       Impact factor: 4.384

Review 8.  Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.

Authors:  Christoph U Correll; Stefan Leucht; John M Kane
Journal:  Am J Psychiatry       Date:  2004-03       Impact factor: 18.112

Review 9.  Unique Effects of Clozapine: A Pharmacological Perspective.

Authors:  Jibran Y Khokhar; Angela M Henricks; Emily D K Sullivan; Alan I Green
Journal:  Adv Pharmacol       Date:  2018-01-12

10.  Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy.

Authors:  G K Thaker; J A Nguyen; M E Strauss; R Jacobson; B A Kaup; C A Tamminga
Journal:  Am J Psychiatry       Date:  1990-04       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.